Immune characteristics correlating with HSV-1 immune control and effect of squaric acid dibutyl ester on immune characteristics of subjects with frequent herpes labialis episodes
- PMID: 30756512
- PMCID: PMC6416766
- DOI: 10.1002/iid3.241
Immune characteristics correlating with HSV-1 immune control and effect of squaric acid dibutyl ester on immune characteristics of subjects with frequent herpes labialis episodes
Abstract
Introduction: Differences in immune characteristics, including immune gene expression by peripheral blood mononuclear cells (PBMCs), correlating with herpes labialis and good or poor immune control of herpes simplex virus type 1 (HSV-1), and how these characteristics change after dosing with squaric acid dibutyl ester (SADBE), were investigated.
Methods: PBMCs were collected from persons positive for IgG against HSV-1 and having frequent, infrequent, or no herpes labialis outbreaks. The PBMCs were tested for proliferation against HSV-1 and a fungal antigen (Candida) and immune gene expression in the presence of HSV-1 and Candida. On day 1 after blood collection the subjects with frequent outbreaks were dosed topically on the arm once with SADBE, and their PBMCs were collected and tested 8 weeks later.
Results: Those with good immune control of their HSV-1 infection (fewer outbreaks) differ from those with poorer immune control in these ways: (1) Greater PBMC proliferation in vitro to HSV-1, HSV-1-infected cell extracts, and Candida considered together (P < 0.01). (2) Higher expression of IFNG and five other immune-related genes (P < 0.05 for each) and lower expression of IL5 and two other immune-related genes (P < 0.05 for each) in PBMCs in vitro stimulated with HSV-1 virus. The subjects with frequent outbreaks were treated once with SADBE, and 56 days later the PBMCs of these subjects differed from PBMCs from the same subjects taken on day 1 before treatment in exactly the same ways listed above as differences between those with good and poor immune control of HSV-1, and at the same levels of significance.
Conclusions: Higher IFNG and lower IL5 expression by PBMCs in the presence of HSV-1 correlate with fewer herpes labialis outbreaks, and a single topical dose of SADBE to the arm of subjects with frequent herpes labialis episodes improves immune response to HSV-1.
Keywords: herpes labialis; herpes simplex; herpesvirus 1; interferon gamma; interleukin-5; squaric acid; squaric acid dibutyl ester.
© 2019 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
Figures










Similar articles
-
Herpes simplex virus-specific immune responses in subjects with frequent and infrequent orofacial recrudescences.Br J Dermatol. 2001 Mar;144(3):459-64. doi: 10.1046/j.1365-2133.2001.04068.x. Br J Dermatol. 2001. PMID: 11259999
-
Immune response to herpes simplex virus in patients with recurrent herpes labialis. II. Relationship between interferon production and cytotoxic responses.Pediatr Res. 1986 Sep;20(9):905-8. doi: 10.1203/00006450-198609000-00020. Pediatr Res. 1986. PMID: 3018660
-
Calcium spirulan derived from Spirulina platensis inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis.J Allergy Clin Immunol. 2016 Jan;137(1):197-203.e3. doi: 10.1016/j.jaci.2015.07.027. Epub 2015 Sep 2. J Allergy Clin Immunol. 2016. PMID: 26341274
-
An update on short-course intermittent and prevention therapies for herpes labialis.Herpes. 2007 Jun;14 Suppl 1:13A-18A. Herpes. 2007. PMID: 17877887 Review.
-
A nurse practitioner's guide to the management of herpes simplex virus-1 in children.Pediatr Nurs. 2008 Jul-Aug;34(4):310-8. Pediatr Nurs. 2008. PMID: 18814565 Review.
Cited by
-
Herpes Simplex Virus 1 MicroRNA miR-H28 Exported to Uninfected Cells in Exosomes Restricts Cell-to-Cell Virus Spread by Inducing Gamma Interferon mRNA.J Virol. 2019 Oct 15;93(21):e01005-19. doi: 10.1128/JVI.01005-19. Print 2019 Nov 1. J Virol. 2019. PMID: 31413129 Free PMC article.
-
Tackling cutaneous herpes simplex virus disease with topical immunomodulators-a call to action.Clin Microbiol Rev. 2025 Mar 13;38(1):e0014724. doi: 10.1128/cmr.00147-24. Epub 2025 Feb 21. Clin Microbiol Rev. 2025. PMID: 39982077 Review.
-
Current landscape in antiviral drug development against herpes simplex virus infections.Smart Med. 2022 Dec 16;1(1):e20220004. doi: 10.1002/SMMD.20220004. eCollection 2022 Dec. Smart Med. 2022. PMID: 39188739 Free PMC article. Review.
References
-
- Woo S. B., Challacombe S. J. Management of recurrent oral herpes simplex infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103:e11–e18. - PubMed
-
- Sarnoff D. S. Treatment of recurrent herpes labialis. J Drugs Dermatol. 2014; 13:1016–1018. - PubMed
-
- Parks C. G., Andrew M. E., Blanciforti L. A., Luster M. I. Variation in the WBC differential count and other factors associated with reporting of herpes labialis: a population‐based study of adults. FEMS Immunol Med Microbiol. 2007; 51:336–343. - PubMed
-
- Lorette G., Crochard A., Mimaud V., Wolkenstein P., Stalder J. F., El Hasnaoui A. A survey on the prevalence of orofacial herpes in France: the INSTANT study. J Am Acad Dermatol. 2006; 55:225–232. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical